Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group

Lorenzo, Gianni; Cole, Bernard F; Panzini, Ilaria; Snyder, Raymond; Holmberg, Stig B; Byrne, Michael; Crivellari, Diana; Colleoni, Marco; Aebi, Stefan; Simoncini, Edda; Pagani, Olivia; Castiglione-Gertsch, Monica; Price, Karen N; Goldhirsch, Aron; Coates, Alan S; Ravaioli, Alberto (2008). Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. Supportive care in cancer, 16(1), pp. 67-74. Berlin: Springer 10.1007/s00520-007-0295-y

Full text not available from this repository. (Request a copy)

GOAL OF THE WORK: Anemia is a common side effect of chemotherapy. Limited information exists about its incidence and risk factors. The objective of this study was to evaluate the incidence of anemia and risk factors for anemia occurrence in patients with early breast cancer who received adjuvant chemotherapy. MATERIALS AND METHODS: We evaluated risk factors for anemia in pre- and post/perimenopausal patients with lymph node-positive early breast cancer treated with adjuvant chemotherapy in two randomized trials. All patients received four cycles of doxorubicin and cyclophosphamide (AC) followed by three cycles of cyclophosphamide, methotrexate, fluorouracil (CMF). Anemia incidence was related to baseline risk factors. Multivariable analysis used logistic and Cox regression. MAIN RESULTS: Among the 2,215 available patients, anemia was recorded in 11% during adjuvant chemotherapy. Grade 2 and 3 anemia occurred in 4 and 1% of patients, respectively. Pretreatment hemoglobin and white blood cells (WBC) were significant predictors of anemia. Adjusted odds ratios (logistic regression) comparing highest versus lowest quartiles were 0.18 (P < 0.0001) for hemoglobin and 0.52 (P = 0.0045) for WBC. Age, surgery type, platelets, body mass index, and length of time from surgery to chemotherapy were not significant predictors. Cox regression results looking at time to anemia were similar. CONCLUSIONS: Moderate or severe anemia is rare among patients treated with AC followed by CMF. Low baseline hemoglobin and WBC are associated with a higher risk of anemia.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Aebi, Stefan and Castiglione-Gertsch, Monica

ISSN:

0941-4355

ISBN:

17629752

Publisher:

Springer

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:02

Last Modified:

20 Mar 2019 11:04

Publisher DOI:

10.1007/s00520-007-0295-y

PubMed ID:

17629752

Web of Science ID:

000251601100009

URI:

https://boris.unibe.ch/id/eprint/27138 (FactScience: 104313)

Actions (login required)

Edit item Edit item
Provide Feedback